MANNKIND CORP (MNKD)
US56400P7069 - Common Stock
Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 564 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. MNKD is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year MNKD was profitable.
MNKD had a positive operating cash flow in the past year.
MNKD had negative earnings in each of the past 5 years.
In the past 5 years MNKD reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of MNKD (4.65%) is better than 94.43% of its industry peers.
With an excellent Return On Invested Capital value of 11.54%, MNKD belongs to the best of the industry, outperforming 96.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.65% | ||
| ROE | N/A | ||
| ROIC | 11.54% |
ROA(3y)-19.1%
ROA(5y)-33.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MNKD (8.07%) is better than 94.43% of its industry peers.
MNKD has a Operating Margin of 21.43%. This is amongst the best in the industry. MNKD outperforms 96.41% of its industry peers.
MNKD has a Gross Margin of 71.91%. This is amongst the best in the industry. MNKD outperforms 83.30% of its industry peers.
In the last couple of years the Gross Margin of MNKD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.43% | ||
| PM (TTM) | 8.07% | ||
| GM | 71.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.96%
GM growth 5Y21.68%
2. Health
2.1 Basic Checks
MNKD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MNKD has been increased compared to 1 year ago.
MNKD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MNKD has been reduced compared to a year ago.
2.2 Solvency
MNKD has an Altman-Z score of -6.42. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.42, MNKD is not doing good in the industry: 67.50% of the companies in the same industry are doing better.
MNKD has a debt to FCF ratio of 16.66. This is a negative value and a sign of low solvency as MNKD would need 16.66 years to pay back of all of its debts.
MNKD has a Debt to FCF ratio of 16.66. This is amongst the best in the industry. MNKD outperforms 92.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 16.66 | ||
| Altman-Z | -6.42 |
ROIC/WACC1.14
WACC10.08%
2.3 Liquidity
A Current Ratio of 4.54 indicates that MNKD has no problem at all paying its short term obligations.
The Current ratio of MNKD (4.54) is comparable to the rest of the industry.
A Quick Ratio of 4.17 indicates that MNKD has no problem at all paying its short term obligations.
MNKD has a Quick ratio of 4.17. This is comparable to the rest of the industry: MNKD outperforms 49.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 141.67% over the past year.
Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 51.30%.
Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 48.13% on average per year.
EPS 1Y (TTM)141.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)51.3%
Revenue growth 3Y45.12%
Revenue growth 5Y48.13%
Sales Q2Q%36.73%
3.2 Future
The Earnings Per Share is expected to grow by 70.58% on average over the next years. This is a very strong growth
Based on estimates for the next years, MNKD will show a very strong growth in Revenue. The Revenue will grow by 20.34% on average per year.
EPS Next Y324.4%
EPS Next 2Y154.72%
EPS Next 3Y108.3%
EPS Next 5Y70.58%
Revenue Next Year46.16%
Revenue Next 2Y30.76%
Revenue Next 3Y25.64%
Revenue Next 5Y20.34%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 129.60, which means the current valuation is very expensive for MNKD.
MNKD's Price/Earnings ratio is rather cheap when compared to the industry. MNKD is cheaper than 92.28% of the companies in the same industry.
MNKD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.41.
The Price/Forward Earnings ratio is 28.88, which means the current valuation is very expensive for MNKD.
Based on the Price/Forward Earnings ratio, MNKD is valued cheaply inside the industry as 93.18% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.69, MNKD is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 129.6 | ||
| Fwd PE | 28.88 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaper than 94.61% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MNKD is valued cheaper than 93.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.89 | ||
| EV/EBITDA | 29.21 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNKD's earnings are expected to grow with 108.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y154.72%
EPS Next 3Y108.3%
5. Dividend
5.1 Amount
MNKD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MANNKIND CORP
NASDAQ:MNKD (1/3/2025, 8:00:01 PM)
After market: 6.59 +0.11 (+1.7%)6.48
-0.12 (-1.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners50.94%
Inst Owner Change11.19%
Ins Owners1.43%
Ins Owner Change-3.75%
Market Cap1.79B
Analysts83.64
Price Target9.61 (48.3%)
Short Float %15.27%
Short Ratio13.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.81%
Min EPS beat(2)-246.98%
Max EPS beat(2)-34.64%
EPS beat(4)1
Avg EPS beat(4)-82.7%
Min EPS beat(4)-246.98%
Max EPS beat(4)50.83%
EPS beat(8)4
Avg EPS beat(8)-13.97%
EPS beat(12)5
Avg EPS beat(12)-13.1%
EPS beat(16)6
Avg EPS beat(16)-11.74%
Revenue beat(2)1
Avg Revenue beat(2)0.86%
Min Revenue beat(2)-7.78%
Max Revenue beat(2)9.49%
Revenue beat(4)3
Avg Revenue beat(4)4.03%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)5
Avg Revenue beat(8)4.04%
Revenue beat(12)8
Avg Revenue beat(12)5.01%
Revenue beat(16)12
Avg Revenue beat(16)7.55%
PT rev (1m)5.81%
PT rev (3m)20.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-28.57%
EPS NY rev (1m)0%
EPS NY rev (3m)32.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 129.6 | ||
| Fwd PE | 28.88 | ||
| P/S | 6.69 | ||
| P/FCF | 61.89 | ||
| P/OCF | 43.02 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.21 |
EPS(TTM)0.05
EY0.77%
EPS(NY)0.22
Fwd EY3.46%
FCF(TTM)0.1
FCFY1.62%
OCF(TTM)0.15
OCFY2.32%
SpS0.97
BVpS-0.76
TBVpS-0.79
PEG (NY)0.4
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.65% | ||
| ROE | N/A | ||
| ROCE | 14.6% | ||
| ROIC | 11.54% | ||
| ROICexc | 32.19% | ||
| ROICexgc | 33.94% | ||
| OM | 21.43% | ||
| PM (TTM) | 8.07% | ||
| GM | 71.91% | ||
| FCFM | 10.81% |
ROA(3y)-19.1%
ROA(5y)-33.07%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.96%
GM growth 5Y21.68%
F-Score9
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 16.66 | ||
| Debt/EBITDA | 7.21 | ||
| Cap/Depr | 196.83% | ||
| Cap/Sales | 4.74% | ||
| Interest Coverage | 2.39 | ||
| Cash Conversion | 65.23% | ||
| Profit Quality | 133.88% | ||
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.17 | ||
| Altman-Z | -6.42 |
F-Score9
WACC10.08%
ROIC/WACC1.14
Cap/Depr(3y)443.89%
Cap/Depr(5y)363.79%
Cap/Sales(3y)14.72%
Cap/Sales(5y)11.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)141.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y324.4%
EPS Next 2Y154.72%
EPS Next 3Y108.3%
EPS Next 5Y70.58%
Revenue 1Y (TTM)51.3%
Revenue growth 3Y45.12%
Revenue growth 5Y48.13%
Sales Q2Q%36.73%
Revenue Next Year46.16%
Revenue Next 2Y30.76%
Revenue Next 3Y25.64%
Revenue Next 5Y20.34%
EBIT growth 1Y715.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y129.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y145.83%
OCF growth 3YN/A
OCF growth 5YN/A